An observational study in PTSD, Autism Spectrum Disorder High-Functioning and OCD, sponsored by Yang I. Pachankis, PhD. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-07-05.
Sponsored by Yang I. Pachankis, PhD · Observational
Autism Spectrum Disorder (ASD) is often accompanied by a variety of other symptoms, such as bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), Social Anxiety Disorder (SAD), Avoidant Personality Disorder (AvPD), Obsessive Compulsive Disorder (OCD), etc. The behavioral and social complications often marginalize the population, impact on life satisfaction, undermined societal values that impact on economic and financial fairness, and so forth. Furthermore, persons with ASD are neurodiverse from standardized pharmacological and clinical cares, and are interpreted disadvantaged in the context of neurotypical treatments.
The research protocol aims to differentiate the neuropharmacological implications of ASD from its behavioral and social implications. Such a differentiation is beneficial to the quality of care for neurodiverse population, both in terms of precision treatment in medical settings, and in terms of psychotherapeutic treatment efficacy in the interpretation of behavioral and social traits.
The study protocol continues from the adverse event of the participant in NCT05711810 trial, after the positive immunological results in the NCT05839236 trial. The intervention medicine continues from Sertraline adjusted on the choice of Selective Serotonin Reuptake Inhibitor (SSRI) in the previous two trials for complex post-traumatic stress disorder (CPTSD) of the participant, and its combined used with Duloxetine in the choice of Selective Norephedrine Reuptake Inhibitor (SNRI) for norephedrine regulations.
The hypothesized target is on the discrete psychiatric intervention centered approach to ASD treatment care. In the PRC where the study is being carried out, amphetamine class medicines are strictly prohibited and defined as illegal substances, regardless of their only proven effect for ASD patient care. Contributed by the sociostructural elements and necessities, black market amphetamine and ketamine have not only emerged in the regime for decades, but also have become a lucrative business. Their recreational uses are also sometimes accompanied by real necessities and needs; black markets cater to the needs but guidance on the usages is based on word-of-mouth stories without professional medical assistances. There is one case the Principal Investigator (PI) collected, that one person, possibly under depression contributed by PTSD, took relatively high dosage of amphetamine and went into a state of psychosis with overwhelming persecution mania. The study protocol, Psychiatric Orders in Psychoanalytic Treatment of ASD, is therefore designed for an evidence-based approach in treating complex psychiatric disorders with psychoanalytic guidance.
2,682 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 601 are open to participants now.
This study's enrollment of 1 is below the median of 150 across 371 observational studies indexed under Stress Disorders, Post-Traumatic.
Browse Stress Disorders, Post-Traumatic studies →Yang I. Pachankis, PhD is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population is currently Asian, and the sociostructural environment of People's Republic of China is implied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The participant started taking SNRI duloxetine 20 mg/night in Jan. 2023, and changed to SSRI sertraline 50 mg/d in Mar. 2023. The apparent positive psychedelic effects did not take effect until increased dosage to sertraline 100mg/d after around one week in Jun. 2023. Duloxetine is planned to be added to the mix thereon.
Diagnostic Test: Psychoanalysis · Drug: sertraline 50mg · Drug: Duloxetine 20 MG · Behavioral: Cognitive Behavioral Therapy
Case-specific psychoanalysis is performed, including the participant's background during birth.
Also known as: Psychodynamic analysis
After the initial assessment of 50 mg/d, the treatment dosage is determined at 100 mg/d.
Also known as: SSRI
Duloxetine is used with 20 mg/night for subsidiary effects with sertraline.
Also known as: SNRI
CBT is tailored to the participant's current activities and life decisions.
Also known as: CBT
Hamilton Anxiety Rating Scale (HAM-A)
Time frame: 90 days
Generalized Anxiety Disorder (GAD-7)
Time frame: 90 days
Dissociative Experiences Scale - II (DES-II)
Time frame: 90 days
The Defeat Scale (D Scale)
Time frame: 90 days
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Time frame: 90 days
Severity Measure for Agoraphobia-Adult
Time frame: 90 days
BPD Check List
Time frame: 90 days
Rosenberg Self-Esteem Scale (RSE)
Time frame: 90 days
Young Schema Questionnaire (YSQ)
Time frame: 90 days
Personality Belief Questionnaire (PBQ)
Time frame: 90 days
Behavioral Satisfaction Questionnaire (X axis)
The X axis score total range -150 to +140, from self-centrism (passive-aggressiveness) to proactive social behaviors.
Time frame: 90 days
Behavioral Satisfaction Questionnaire (Y axis)
The Y axis score total range -200 to +195, from inhibition to excitation of the hypothalamic-pituitary-adrenal (HPA) axis in daily lives.
Time frame: 90 days
Heart Rate
Heart rate is used to correlate to the participant's mode change.
Time frame: 90 days
Systolic Blood Pressure
Systolic blood pressure is measured for reference on psychoneurotic correlations.
Time frame: 90 days
Diastolic Blood Pressure
Diastolic blood pressure is measured for reference on possible side-effects with dizziness etc.
Time frame: 90 days
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD is being shared on Open Science Framework with the DOI: 10.17605/OSF.IO/2MGJK.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: The data will be available during the study process, and the archives after completion will stay available.
Access criteria: Public.
Data sharing details ↗ · doi.org
This study is active, not recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
Yang I. Pachankis, PhD